Compare
Integrated Biopharma Inc vs Agios Pharmaceuticals, Inc. vs Q32 Bio Inc. vs Nektar Therapeutics
| Latest fiscal year | Integrated Biopharma Inc INBP | Agios Pharmaceuticals, Inc. AGIO | Q32 Bio Inc. QTTB | Nektar Therapeutics NKTR |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $43.87M | $54.03M | $53.74M | $55.23M |
| Revenue growth (YoY) | -19.3% | +48.0% | n/a | -43.9% |
| Gross margin | 1.8% | 88.3% (computed) | n/a | n/a |
| Operating margin | -6.2% | -873.9% | 31.5% | -253.7% |
| Net margin | -6.5% | -764.0% | 55.5% | -297.1% |
| Net income | -$2.84M | -$412.78M | $29.82M | -$164.08M |
| EPS (Diluted) | -$0.09 | -$7.12 | $2.42 | -$9.73 |
| Operating cash flow | $1.24M | -$372.98M | -$33.54M | -$208.51M |
| Free cash flow | $895.0K | -$377.29M | -$33.54M | -$208.68M |
| Cash & equivalents | $4.47M | $89.13M | $48.30M | $15.12M |
| Total assets | $25.34M | $1.30B | $61.78M | $280.41M |
| Total liabilities | $7.67M | $104.11M | $19.76M | $190.57M |
| Shareholders' equity | $17.67M | $1.19B | $42.01M | $89.83M |
| Return on year-end equity | -16.1% | -34.6% | 71.0% | -182.6% |
| Shares outstanding | 31.06M | 58.45M | 12.86M | 20.38M |
Revenue, most recent five fiscal years
| Fiscal year | Integrated Biopharma Inc | Agios Pharmaceuticals, Inc. | Q32 Bio Inc. | Nektar Therapeutics |
|---|---|---|---|---|
| Latest | $43.87M Ended 2026-06-30 | $54.03M Ended 2025-12-31 | $53.74M Ended 2025-12-31 | $55.23M Ended 2025-12-31 |
| 1 year earlier | $54.35M Ended 2025-06-30 | $36.50M Ended 2024-12-31 | $0 Ended 2024-12-31 | $98.43M Ended 2024-12-31 |
| 2 years earlier | $50.32M Ended 2024-06-30 | $26.82M Ended 2023-12-31 | -$6.65M Ended 2023-12-31 | $90.12M Ended 2023-12-31 |
| 3 years earlier | $50.67M Ended 2023-06-30 | $14.24M Ended 2022-12-31 | n/a | $92.06M Ended 2022-12-31 |
| 4 years earlier | $56.25M Ended 2022-06-30 | $0 Ended 2021-12-31 | n/a | $101.91M Ended 2021-12-31 |